Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Swedish Orphan Biovitrum has released poster clinical Phase II results from the first study showing that Kiobrina added to infant formula improve growth of preterm infants as compared to placebo after 1 week of treatment.
Subscribe to our email newsletter
The poster is presented at ‘The Power of Programming 2010 International conference on developmental origins of health and disease’ in Munich, Germany.
Swedish Orphan Biovitrum claimed that Kiobrina is a recombinant human bile-salt-stimulated lipase (rhBSSL) developed by it, used to improve growth and development in preterm infants. The rationale for adding rhBSSL to pasteurised breast milk or infant formula is to restore the natural lipase activity level that is either lost on pasteurisation or totally absent in formula.
Peter Edman, CSO of Swedish Orphan Biovitrum, said: “This is an interesting project and Kiobrina holds a great opportunity to fill a medical need in neonatal care. Based on these results and those from a second clinical Phase II trial of Kiobrina in pasteurised mother’s milk we are now planning for a Phase III study in preterm infants.”